Ballad Health Reports FY20 Second Quarter Results

    NEXT STORY
    Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis
    PREV STORY
    ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Celyad Announces Third Quarter 2017 Business Update

    MONT-SAINT-GUIBERT, Belgium, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a ...

    author_avatar
    NASDAQ Market News

    Aravive Announces Participation at Wedbush PacGrow Healthcare Conference

    author_avatar
    NASDAQ Market News

    Sorrento Therapeutics CAR-T Manufacturing Capacity Expanded With Opening of East Coast GMP Site in Addition to Primary West Coast Facility

    SAN DIEGO, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento"), announced ...

    author_avatar
    NASDAQ Market News